Sutro Biopharma (STRO) – Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Sutro Biopharma (NASDAQ: STRO) recently:

• 8/13/2026 – Sutro Biopharma had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/13/2026 – Sutro Biopharma had its price target lowered by Citizens Jmp from $41.00 to $34.00. They now have a “market outperform” rating on the stock.
• 8/13/2026 – Sutro Biopharma had its “outperform” rating reaffirmed by Wedbush. They now have a $60.00 price target on the stock.
• 8/7/2026 – Sutro Biopharma was given a new $48.00 price target by Stifel Nicolaus. They now have a “buy” rating on the stock.
• 8/5/2026 – Sutro Biopharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.